Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company

Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock

Sufficient working capital obtained to fund operations for near term